A5035072016- Intracerebral and Subarachnoid Hemorrhage Research
- Alzheimer's disease research and treatments
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Cerebrovascular and genetic disorders
- Dementia and Cognitive Impairment Research
- Hormonal and reproductive studies
- Sleep and Wakefulness Research
- Neuroinflammation and Neurodegeneration Mechanisms
- Neurological Disease Mechanisms and Treatments
- S100 Proteins and Annexins
- Protease and Inhibitor Mechanisms
- Circadian rhythm and melatonin
- Parkinson's Disease Mechanisms and Treatments
- Liver Disease and Transplantation
- Acute Ischemic Stroke Management
- Adrenal Hormones and Disorders
- Pituitary Gland Disorders and Treatments
- Phytoestrogen effects and research
- Neurological disorders and treatments
- Intracranial Aneurysms: Treatment and Complications
- Neural dynamics and brain function
- Thyroid Cancer Diagnosis and Treatment
- Organ Transplantation Techniques and Outcomes
- Cancer-related Molecular Pathways
- Renal cell carcinoma treatment
Radboud University Nijmegen
2017-2024
Radboud University Medical Center
2017-2024
Max Planck Institute of Psychiatry
2024
University Medical Center
2024
Nia Association
2022
ID Genomics (United States)
2022
Radboud Institute for Molecular Life Sciences
2021
Ablynx (Belgium)
2018
Spanish National Cancer Research Centre
2014
Erasmus University Rotterdam
2005
Vascular amyloid β (Aβ) accumulation is the hallmark of cerebral angiopathy (CAA). The composition cerebrospinal fluid (CSF) CAA patients may serve as a diagnostic biomarker CAA. We studied potential peptides Aβ38, Aβ40, Aβ42, and Aβ43 in with sporadic (sCAA), hereditary Dutch-type (D-CAA), Alzheimer disease (AD).
Recent evidence shows that during slow-wave sleep (SWS), the brain is cleared from potentially toxic metabolites, such as amyloid-beta protein. Poor or elevated cortisol levels can worsen clearance, leading to formation of amyloid plaques, a neuropathological hallmark Alzheimer disease. Here, we explored how nocturnal neural and endocrine activity affects fluctuations in peripheral blood.
Abstract Cerebral amyloid angiopathy (CAA) is a form of small vessel disease characterised by the progressive deposition β protein in cerebral vasculature, inducing symptoms including cognitive impairment and haemorrhages. Due to their accessibility homogeneous phenotypes, animal models are advantageous platforms study diseases like CAA. Untargeted proteomics studies CAA rat (e.g. rTg-DI) patients provide opportunities for identification novel biomarkers We performed untargeted,...
Cerebral small vessel disease (SVD) is a frequent pathology in aging and contributor to the development of dementia. Plasma Aβ (amyloid β) levels may be useful as early biomarker, but role plasma SVD remains elucidated. We investigated association with severity progression markers.We studied 487 participants from RUN DMC study (Radboud University Nijmegen Diffusion Tensor Magnetic Resonance Imaging Cohort) whom 258 underwent 3 MRI assessments during 9 years. determined baseline Aβ38, Aβ40,...
The determination of the increased release adrenal steroids after stimulation with corticotrophin was introduced for diagnosis disorders ten years ago by Thorn and his associates. It proved to be a most reliable test function. In meantime, such examinations became significant, apart from organic lesions glands. With administration hormones pituitary glands procedures give some insight into principles concerned regulation As far as therapeutic use corticoids is tests information about...
Abstract Background The diagnosis of probable cerebral amyloid angiopathy (CAA) is currently mostly based on characteristics brain MRI. Blood biomarkers would be a cost-effective, easily accessible diagnostic method that may complement by MRI and aid in monitoring disease progression. We studied the potential plasma Aβ38, Aβ40, Aβ42 patients with hereditary Dutch-type CAA (D-CAA) sporadic (sCAA). Methods All Aβ peptides were quantified immunoassays discovery cohort (11 presymptomatic D-CAA...
Abstract The aim of our study was to investigate cerebrospinal fluid (CSF) tryptic peptide profiles as potential diagnostic biomarkers for the discrimination parkinsonian disorders. CSF samples were collected from individuals with parkinsonism, who had an uncertain diagnosis at time inclusion and followed up 12 years in a longitudinal study. We performed shotgun proteomics identify peptides Parkinson’s disease (PD, n = 10), multiple system atrophy patients (MSA, 5) non-neurological controls...
Cerebrospinal fluid (CSF) platelet-derived growth factor receptor-β (PDGFRβ) has been proposed as a biomarker of blood-brain barrier (BBB) breakdown. We studied PDGFRβ levels for cerebral amyloid angiopathy (CAA), amnestic mild cognitive impairment (aMCI), or Alzheimer's disease (AD).CSF were quantified by enzyme-linked immunosorbent assay in patients with CAA, aMCI/AD, and matched controls. In aMCI/AD we evaluated CSF both clinical phenotype using the AT(N) classification system defined...
Abstract Background To evaluate the potential of cerebrospinal fluid (CSF) levels matrix metalloproteinases and tissue-type inhibitors (MMP; TIMP), ratios MMPs to TIMPs, function as biomarkers for sporadic or hereditary cerebral amyloid angiopathy (CAA). Methods CSF concentrations MMP-2, MMP-9 MMP-14, well tissue TIMP-1, TIMP-2 TIMP-3, were determined using immunoassays. These assays applied two, independent study groups CAA (sCAA) ( n = 28/43) control subjects 40/40), pre-symptomatic 11)...
Alzheimer's disease (AD) and cerebral amyloid angiopathy (CAA) share pathogenic pathways related to amyloid-β deposition. Whereas AD is known affect synaptic function, such an association for CAA remains yet unknown.We therefore aimed investigate dysfunction in CAA.Multiple reaction monitoring mass spectrometry was used quantify cerebrospinal fluid (CSF) concentrations of 15 proteins patients, age- sex-matched cognitively unimpaired controls.We included 25 patients with CAA, 49 AD, controls....
Background: Tyrosine kinase inhibitors (TKIs) have achieved remarkable clinical results in medullary thyroid carcinoma (MTC) patients. However, the considerable variability patient response to treatment with TKIs remains largely unexplained. There is evidence that it could be due, at least part, alterations genes associated disease via their effect on expression of TKI targets. The objective this study was evaluate influence RAS mutations levels MTC tumors eight key target proteins. Methods:...
We investigated the potential of apolipoprotein D (apoD) as cerebrospinal fluid (CSF) biomarker for cerebral amyloid angiopathy (CAA) after confirmation its association with CAA pathology in human brain tissue.The apoD was analysed occipital lobe tissue (n = 9), Alzheimer's disease (AD) 11) and healthy control cases 11). ApoD levels were quantified an age- sex-matched CSF cohort patients 31), AD 27) non-neurological controls 67). The effects confounding factors (age, sex, serum levels) on...
Abstract Brain amyloid‐β (Aβ) deposits are key pathological hallmarks of both cerebral amyloid angiopathy (CAA) and Alzheimer's disease (AD). Microvascular in CAA mainly consist the Aβ 40 peptide, whereas 42 is predominant variant parenchymal plaques AD. The relevance pathogenesis diagnostic accuracy various other isoforms remain understudied. We aimed to investigate biomarker potential cerebrospinal fluid (CSF) differentiate from AD pathology. included 25 patients with probable CAA, 50...
Cerebral amyloid angiopathy (CAA) is a highly prevalent and progressive pathology, involving amyloid-β (Aβ) deposition in the cerebral blood vessel walls. CAA associated with an increased risk for intracerebral hemorrhages (ICH). Insight into molecular mechanisms pathology urgently needed, to develop additional diagnostic tools allow reliable early diagnosis of obtain novel leads development targeted therapies. Tissue inhibitor matrix metalloproteinases 4 (TIMP4) cardiovascular functioning...
Neuroleukin (NLK) is a protein with neurotrophic properties and present in proportion of senile plaques amyloid laden vessels. It has been suggested that NLK part neuroprotective response to β-induced cell death. The aim our study was investigate the value cerebrospinal fluid (CSF) levels as biomarker vascular deposition patients cerebral angiopathy (CAA) amnestic mild cognitive impairment (aMCI) Alzheimer's disease (AD). CSF were quantified by ELISA CAA (n = 25) controls 27) two independent...
Abstract Background Recent evidence shows that during slow-wave sleep (SWS), the brain is cleared from potentially toxic metabolites, such as amyloid-beta protein. Poor or elevated cortisol levels can worsen clearance, leading to formation of amyloid plaques, a neuropathological hallmark Alzheimer’s disease. Here, we explore how nocturnal neural and endocrine activity affects fluctuations in peripheral blood reflection cerebral clearance. Methods Simultaneous polysomnography all-night...
Abstract Background Prior research conducted in model rats of CAA Type 1 (rTg-DI) identified a range cerebrospinal fluid biomarker candidates associated with sCAA pathology. This list potential biomarkers includes the lysosomal proteases cathepsins B and S (CTSB/CTSS) hexosaminidase (HEXB). It is yet unknown if these findings obtained rTg-DI translate to differential protein levels and/or enzyme activities (CSF) patients. In this study, we attempted validate CTSB, CTSS HEXB CSF as for human...
Sporadic cerebral amyloid angiopathy (sCAA) is a disease characterised by the progressive deposition of beta (Aβ) in vasculature, capable causing variety symptoms, from (mild) cognitive impairment, to micro- and major haemorrhagic lesions. Modern diagnosis sCAA relies on radiological detection late-stage hallmarks disease, complicating early potential interventions progression. Our goal this study was identify validate novel biomarkers for sCAA. We performed proximity extension assay (PEA)...